2 March 2026
We are delighted to announce the appointment of Christian Miculka as a new member of the MPP Governance Board. Christian is a chemist with more than 30 years of experience in the human and animal health pharmaceutical industries. He has held senior leadership roles across R&D, innovation strategy, and corporate governance in Germany, France, and the United States. As Project Integrator for the team that developed the world’s first approved COVID-19 vaccine and the first available for mass vaccination at BioNTech, he witnessed firsthand how the right people, culture, and mindset can translate bold ambition into global impact.
Prior to BioNTech, Christian led the development of a new innovation strategy for Sanofi’s Diabetes Division and served as Chief of Staff to Sanofi’s R&D President, overseeing R&D governance, committee operations, and portfolio decision-making. Earlier in his career in animal health R&D, he led the discovery of arpraziquantel, which now forms the basis of treatment for preschool-aged children with schistosomiasis and is being rolled out by the Pediatric Praziquantel Consortium and Merck KGaA in 2025.
Christian currently supports global health initiatives pro bono, teaches at leading business schools, and advises biopharmaceutical companies and investors on strategy, innovation, and governance.
The Governance Board is MPP’s highest decision-making authority, responsible for setting policies and strategies, overseeing work plans and financial matters, and monitoring performance. Christian’s deep scientific expertise, strategic leadership, and global outlook will be invaluable as we advance MPP’s mission to improve access to essential medicines worldwide.
More information about MPP’s Governance Board
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.